You are here: Industry Insights > BNT162

News List

FDA grants Fast Track designation to two COVID-19 vaccines europeanpharmaceuticalreview
July 14, 2020
Two investigational SARS-CoV-2 vaccine candidates, BNT162b1 and BNT162b2, currently in clinical trials have been granted Fast Track designation by the FDA.
EIB Provides BioNTech with Debt Financing for COVID-19 Vaccine Development, Manufacturing americanpharmaceuticalreview
June 23, 2020
The European Investment Bank (EIB) and BioNTech SE concluded a €100 million debt financing agreement to support the development of BNT162, the company’s COVID-19 vaccine program.
European Investment Bank to provide BioNTech with up to €100 million in debt financing for COVID-19 vaccine development and manufacturing expresspharma
June 12, 2020
mRNA vaccines consist of genetic material, called messenger RNA, that provides instructions for a human cell to make a target protein, or immunogen, which activates the body’s immune response against the respective virus.
mRNA-based vaccine technology innovate approach to treating COVID-19 expresspharma
May 29, 2020
Over 150 COVID-19 vaccines are currently under development by biopharma companies and research organisations around the world.
Pfizer, BioNTech dose first participants in Covid-19 vaccine trial in US pharmaceutical-business-review
May 08, 2020
Pfizer and Biopharmaceutical New Technologies (BioNTech) have dosed the first participants of a phase 1/2 trial for their Covid-19 vaccine candidate BNT162 in the US.
Germany to begin first clinical trial of COVID-19 vaccine candidate europeanpharmaceuticalreview
April 24, 2020
A Phase I/II clinical trial for BioNTech’s BNT162 vaccine programme to prevent COVID-19 infection has been granted approval in Germany.
Germany approves trials of COVID-19 vaccine candidate expresspharma
April 23, 2020
The trial, only the fourth worldwide of a vaccine targeting the virus, will be initially conducted on 200 healthy people, with more subjects, including some at higher risk from the disease, to be included in a second stage, German vaccines regulator the P

Previous page 1 2 Next page